Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Payables (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Payables for 5 consecutive years, with $520709.0 as the latest value for Q4 2025.

  • Quarterly Payables fell 65.98% to $520709.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $520709.0 through Dec 2025, down 65.98% year-over-year, with the annual reading at $1.2 million for FY2025, N/A changed from the prior year.
  • Payables for Q4 2025 was $520709.0 at Neuphoria Therapeutics, down from $1.4 million in the prior quarter.
  • The five-year high for Payables was $1.5 million in Q4 2024, with the low at $520709.0 in Q4 2025.
  • Average Payables over 4 years is $1.1 million, with a median of $1.2 million recorded in 2024.
  • The sharpest move saw Payables increased 23.62% in 2023, then tumbled 65.98% in 2025.
  • Over 4 years, Payables stood at $1.1 million in 2022, then rose by 23.62% to $1.4 million in 2023, then increased by 11.04% to $1.5 million in 2024, then crashed by 65.98% to $520709.0 in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $520709.0, $1.4 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.